Introducing
Precisebreast
PreciseBreastTM is designed specifically to work within current genomic testing models, speeding the process of treatment planning for many patients. It assesses risk through the Morphology Feature Array®, combining seven morphologic features and four clinical features to provide accurate and reliable results in days, rather than weeks, at 20% the cost of gene expression testing.
how precisebreast works
PreciseBreast deploys visual AI to analyze the cellular morphology of tissue samples already collected – the same slides pathologists use for tumor grading. The Morphology Feature Array® then objectively classifies patients into two cohorts of low and high risk of tumor recurrence in ~48 hours at 20% the cost of gene expression testing. Oncologists can now confidently discuss results weeks faster than in the past to relieve patient anxiety and to allow for a more comprehensive shared decision making process.
With PreciseBreast, patients - and their physicians - gain clarity, peace of mind, and an objective data point to base decisions on weeks sooner than they would with tumor grading and gene expression testing alone.
Healthcare systems benefit with meaningful cost savings generated by the low risk patients who may not need further expensive gene expression testing.
PreciseBreast requires no additional procedures or specialized staff for specimen collection, and it can be accessed from any geographical area in the US or the world.
Analytic validation of the PreciseBreast technology
98%
Precision & Reproducibility
Tumor Segmentation
<2%
Variation of Assay Risk Score
Analytical validation of PreciseBreast demonstrates high precision across key factors (Fernandez, G., Zeineh, J. et al. Clinical Breast Cancer 2023 (NYSDOH))
Using PreciseBreastTM as well as gene expression or visual pathologic analysis delivers benefits for patients, physicians, and payors.
.svg)
Data to drive precise reporting of tumor recurrence risk
Faster results lessen anxiety for patients
.svg)
Lower overall costs for treatment and testing
Availability to 100% of eligible patients
Dec 9, 2024
COTA Inc., a leader in real-world data (RWD) and analytics for oncology, PreciseDx, an innovator in AI-powered digital pathology focused on oncology diagnostics, and Baptist Health South Florida today announced new study results validating the artificial intelligence (AI)-enabled PreciseBreast™ test is equivalent to the Oncotype DX test at predicting breast cancer recurrence.
See More
Dec 9, 2024
COTA Inc., a leader in real-world data (RWD) and analytics for oncology, PreciseDx, an innovator in AI-powered digital pathology focused on oncology diagnostics, and Baptist Health South Florida today announced new study results validating the artificial intelligence (AI)-enabled PreciseBreast™ test is equivalent to the Oncotype DX test at predicting breast cancer recurrence.
See More
Dec 6, 2024
A study from PreciseDx showed that its artificial-intelligence-guided pathology test could help predict a patient’s chances of their breast cancer returning on par with a leading genomic approach.
See More
Dec 6, 2024
A study from PreciseDx showed that its artificial-intelligence-guided pathology test could help predict a patient’s chances of their breast cancer returning on par with a leading genomic approach.
See More
Nov 20, 2024
World-Renowned Breast Cancer Oncology and Pathology Experts to Advise Company on the Advancement of its AI-Powered PreciseBreastTM Risk of Recurrence Assessment and Product Portfolio
See More
Nov 20, 2024
World-Renowned Breast Cancer Oncology and Pathology Experts to Advise Company on the Advancement of its AI-Powered PreciseBreastTM Risk of Recurrence Assessment and Product Portfolio
See More
Contact us today to learn more about PreciseBreast.
